Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye...
Date First Received: April 25, 2007
Last Updated: April 26, 2007
Verified by: Stanford University, April 2007
Clinical Trial Phase: N/A | Start Date: April 2007
Overall Status: Recruiting
Estimated Enrollment: 100
Brief Summary
Official Title: “Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour”
Condition Keyword(s):
Intervention(s):
Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox).
The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.
Study Type: Interventional
Study Design: Prevention, Randomized, Single Blind, Active Control, Factorial Assignment, Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: gatifloxacin, moxifloxacin
Outcome Measures for this Clinical Trial
Primary Measures
- Antibiotic killing of conjunctival bacterial flora 1 hour after application
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age- older than 50 years of age
- Diagnosis- Cataract or had cataract surgery
Exclusion Criteria:
- Systemic or topical antibiotic treatment within 30 days
- Use of systemic or topical steroids
- Active ocular infection
- Ocular surgery in the past 6 months
- Allergy to fluoroquinolones
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 50 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Stanford University
Overall Clinical Trial Officials and Contacts
Christopher Ta, MD Principal Investigator Stanford University
Overall Contact: Miri Englander, BA 650 804 8408 MiriMD@Stanford.edu
Related Publications
References
Ta CN, He L, Nguyen E, De Kaspar HM. Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative Staphylococcus. Eur J Ophthalmol. 2006 May-Jun;16(3):359-64.
Mino de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005 Apr;139(4):730-3.
de Kaspar HM, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma. 2004 Dec;13(6):507-9.
Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, Mino de Kaspar H. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 2003 Oct;110(10):1946-51.
Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Mino De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002 Nov;109(11):2036-40; discussion 2040-1.
Additional Information
Information obtained from ClinicalTrials.gov on March 10, 2010
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00466570
Study ID Number: 8924
ClinicalTrials.gov Identifier: NCT00466570
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
